Adicet Bio, Inc

@Adicet is pleased to announce that we’ve dosed the first patient in the Phase 1 clinical trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma (ccRCC).   This is a significant milestone for Adicet as we advance our first #gammadelta 1 #CART #celltherapy product candidate for the treatment of solid tumors, one of the highest unmet needs in #oncology. Patients with ccRCC, the most common type of #kidneycancer, have a pressing need for safe and effective treatments, as current therapies offer limited benefits for patients with advanced disease. Based on ADI-270’s encouraging preclinical data generated to date, we believe ADI-270 has the potential to offer a promising advancement for solid tumors.    Enrollment is underway; we look forward to enrolling patients with metastatic/advanced clear cell #renalcellcarcinoma and anticipate sharing preliminary clinical data from the trial in the first half of 2025. To learn more about participating in this #clinicaltrial including becoming a study site, email clinicaltrials@adicetbio.com #clinicaltrials #biotech #biotechresearch #biotechinvesting #patientcare

Wow, what a week at the American College of Rheumatology Annual Meeting, #ACR24! We had a wonderful time connecting with so many passionate researchers, clinicians, and patient advocates who share our mission to improving the lives of people living with serious #autoimmune conditions. It was an honor to share our tissue-homing and #bcell-depleting data and to listen to all of the new advances being shared – we’re inspired more than ever to work tirelessly on behalf of patients. As we head into 2025, we’re excited to continue collaborating with the rheumatology community to help advance novel therapies, including our #offtheshelf #gammadelta #CART cell therapy for patients with #lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic #sclerosis (SSc), idiopathic inflammatory myopathy (IIM or #myositis), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV). #rheumatology #clinicaltrials #biotech #biotechresearch 

#ACR24, look forward to seeing you at our Oral Presentation in Room 144ABC at Noon EST today!   Dr. Monica Moreno will present clinical biomarker data for ADI-001, our #offtheshelf #gammadelta #CART #celltherapy demonstrating characteristics essential for treatment of #autoimmune diseases, including robust tissue homing and complete CD19+ #Bcell depletion in secondary lymphoid tissue.   See you soon!   To learn more about this therapeutic approach or how to become a study site in this #clinicaltrial, visit https://lnkd.in/gnK3RvhJ or email clinicaltrials@adicetbio.com #rheumatology #clinicaltrials #biotech #biotechresearch

Marking the first #gammadelta #CART #celltherapy with the potential to address solid tumors entering clinical trials, Adicet opens enrollment for the ADI-270 Phase 1 clinical study in renal cell carcinoma!   Solid tumors represent one of the highest unmet medical needs in #oncology and have yet to benefit from the breakthroughs observed with CAR T cell therapies in hematologic malignancies. Emerging data from ADI-270, our armored #allogeneic #offtheshelf gamma delta 1 CAR T cell therapy targeting CD70 positive #cancers, have shown potential in addressing this gap.    At the recent #ASGCT conference, we presented preclinical data in which ADI-270 demonstrated significant #tumor infiltration, resistance to the immunosuppressive tumor microenvironment, and potent activity via CAR and innate-mediated targeting, highlighting its potential for treating solid tumors.     We look forward to enrolling patients with metastatic/advanced clear cell renal cell carcinoma and anticipate sharing preliminary clinical data from the trial in the first half of 2025.   To learn more about participating in this #clinicaltrial including becoming a study site, email clinicaltrials@adicetbio.com #clinicaltrials #biotech #biotechresearch

We are pleased to announce that we have dosed the first lupus nephritis patient in the ADI-001 autoimmune clinical trial!   This marks an important step forward in our mission to deliver best-in-class #gammadelta #CART #celltherapies for #patients fighting #autoimmune diseases and cancer.   With the clinical biomarker data being presented at #ACR24 demonstrating robust tissue homing and complete CD19+ B cell depletion in peripheral blood and secondary lymphoid tissue, ADI-001 has the potential to be a transformative off-the-shelf treatment option for several autoimmune diseases.   We are committed to advancing ADI-001 in a basket study across six autoimmune indications including #lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic #sclerosis (SSc), idiopathic inflammatory myopathy (IIM or #myositis), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV).     We thank everyone working tirelessly to advance this study with the shared passion of addressing the significant unmet medical needs of patients who urgently require innovative and effective new treatment options.   To learn more about this therapeutic approach or how to become a study site in this #clinicaltrial, visit https://lnkd.in/gnK3RvhJ or email clinicaltrials@adicetbio.com #rheumatology #clinicaltrials #bcell #biotech #biotechresearch

We are pleased to present clinical biomarker data for ADI-001, our #offtheshelf #gammadelta #CART #celltherapy, in an oral session at the American College of Rheumatology (ACR) Convergence 2024!    The data demonstrate characteristics essential for treatment of #autoimmune diseases, including robust tissue homing and complete CD19+ #Bcell depletion in secondary lymphoid tissue.    The hope for new #celltherapies in development is for one dose to help #reset the immune system so patients can achieve sustained disease remission, no longer requiring chronic medications and the challenges associated with their long-term use.   We are committed to advancing ADI-001 in a basket study across six autoimmune indications including #lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic #sclerosis (SSc), idiopathic inflammatory myopathy (IIM or #myositis), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV)  . This highlights our focus on addressing the significant unmet medical needs of patients who urgently require innovative and effective new treatment options.   To learn more about this therapeutic approach or how to become a study site in this #clinicaltrial, visit https://lnkd.in/gnK3RvhJ or email clinicaltrials@adicetbio.com #ACR24 #rheumatology #clinicaltrials #biotech #biotechresearch

Don’t miss the latest update on our ADI-270 oncology program!    VP, Nonclinical Development, Shon Green, Ph.D. presents data showing enhanced preclinical potency and persistence in multiple oncology models in an oral session at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, this week!   ADI-270, our first ever gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors, was granted Fast Track Designation by the FDA earlier this year and is being studied in various solid tumors including renal cell carcinoma (RCC).   ADI-270 is an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70-positive cancers. CD70 is a compelling target due to its high expression in both solid and hematological malignancies.    We’re inspired to advance this novel program on behalf of patients. To learn more about participating in this #clinicaltrial, email clinicaltrials@adicetbio.com   #ASGCTAdvancing24 #CART #celltherapy #gammadelta #clinicaltrials #cancer #oncology #solidtumors #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf  

We are pleased to announce that FDA has granted clearance of an IND amendment to evaluate ADI-001 in two additional indications, Idiopathic Inflammatory Myopathy (IIM) and Stiff Person Syndrome (SPS)!   This acceptance builds on our recent momentum, expanding our efforts to six #autoimmune indications as we aim to bring our differentiated gamma delta T cell therapy candidates to more patients in need of new treatment options.    In addition to IIM and SPS, ADI-001 is also being studied in systemic #lupus erythematosus (#SLE), lupus nephritis (LN), systemic #sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV). With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue (characteristics important in autoimmune treatment), ADI-001 is uniquely differentiated with the goal to bring durable remissions and provide an immune reset for various autoimmune conditions. We are inspired by the idea of bringing to #patients a potential paradigm shift in the treatment of autoimmune diseases. To learn more about participating in this #clinicaltrial, email clinicaltrials@adicetbio.com.   We also have updated biomarker data being presented in an oral session at #ACRConvergence2024 next month – be sure to tune into that, November 19! #CART #celltherapy #gammadelta #clinicaltrials #autoimmune #autoimmuneclinicaltrials #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

We are pleased to announce that we have activated clinical sites and are initiating enrollment for the Phase 1 trial of ADI-001 in autoimmune diseases!   This follows the U.S. Food and Drug Administration’s (FDA) decision to grant Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV #lupus nephritis (LN) and clearance from FDA to develop ADI-001 in four #autoimmune indications including LN, systemic lupus erythematosus (#SLE), systemic #sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV).   With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue (characteristics important in autoimmune treatment), ADI-001 is uniquely differentiated with the goal to bring durable remissions and provide an immune reset for various autoimmune conditions. We are inspired by the idea of bringing to #patients a potential paradigm shift in the treatment of autoimmune diseases. To learn more about participating in this #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com. #CART #celltherapy #gammadelta #clinicaltrials #autoimmune #autoimmuneclinicaltrials #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

Leading the way for cell therapy advancements in autoimmune indications, we’re pleased for our CSO, Dr. Blake Aftab to share data insights from our off-the-shelf #gammadelta CAR T cell program today at the #CARTCR2024 Summit! In a review of clinical biomarker data, the findings highlight ADI-001's robust tissue trafficking and complete B cell depletion in tissue, making it a potential best-in-class #allogeneic #celltherapy for the treatment of #autoimmune disease. We look forward to continuing to study ADI-001 in various autoimmune indications including #lupus nephritis (LN), systemic lupus erythematosus (#SLE), systemic sclerosis (SSc or #scleroderma) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (#AAV) To learn more about participating in this #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com #CART #autoimmune #autoimmuneclinicaltrials #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf